Sex-specific effect of body weight gain on systemic inflammation in subjects with COPD: Results from the SAPALDIA cohort study 2

European Respiratory Journal

Volumn 34, Issue 2, 2008, Pages 332-339

  Bridevaux, P O ^a   Gerbase, M W ^a   Schindler, C ^b   Felber Dietrich, D ^b   Curjuric, I ^b   Dratva, J ^b   Ackermann Liebrich, U ^b   Probst Hensch, N M ^c   Gaspoz, J M ^a   Rochat, T ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Forced expiratory volume in 1 s decline; Obesity; Sex differences; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CORRELATION ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AIR POLLUTANTS; BODY WEIGHT; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEX FACTORS; SMOKING; WEIGHT GAIN;

EID: 69249108874     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00162608     Document Type: Article

References (44)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
2. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
3. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881.
4. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir Care 2002; 47: 1184-1199.
5. Machado MC, Krishnan JA, Buist SA, et al. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 524-529.
6. Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men? Clin Chest Med 2004; 25: 331-341.
7. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
8. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
9. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849-853.
10. Zureik M, Kauffmann F, Touboul PJ, et al. Association between peak expiratory flow and the development of carotid atherosclerotic plaques. Arch Intern Med 2001; 161: 1669-1676.
11. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640-2646.
12. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
13. Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004; 109: 3022-3028.
14. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology 2002; 13: 561-568.
15. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med 2007; 175: 458-463.
16. Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ 2005; 172: 1199-1209.
17. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
18. Clarke R, Emberson JR, Breeze E, et al. Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. Eur Heart J 2008; 29: 800-809.
19. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
20. Ackermann-Liebrich U, Kuna-Dibbert B, Probst-Hensch NM, et al. Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991-2003: methods and characterization of participants. Soz Praventivmed 2005; 50: 245-263.
21. Martin BW, Ackermann-Liebrich U, Leuenberger P, et al. SAPALDIA: methods and participation in the cross-sectional part of the Swiss Study on Air Pollution and Lung Diseases in Adults. Soz Praventivmed 1997; 42: 67-84.
22. Downs SH, Schindler C, Liu LJ, et al. Reduced exposure to PM10 and attenuated age-related decline in lung function. N Engl J Med 2007; 357: 2338-2347.
23. Kunzli N, Kuna-Dibbert B, Keidel D, et al. Longitudinal validity of spirometers - a challenge in longitudinal studies. Swiss Med Wkly 2005; 135: 503-508.
24. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
25. Fletcher CM, Peto R, Tinker CM, et al. The Natural History of Chronic Bronchitis and Emphysema. Oxford, Oxford University Press, 1976.
26. Shaaban R, Leynaert B, Soussan D, et al. Physical activity and bronchial hyperresponsiveness: European Community Respiratory Health Survey II. Thorax 2007; 62: 403-410.
27. Nystad W, Samuelsen SO, Nafstad P, et al. Association between level of physical activity and lung function among Norwegian men and women: the HUNT study. Int J Tuberc Lung Dis 2006; 10: 1399-1405.
28. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
29. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
30. Viegi G, Pistelli F, Sherrill DL, et al. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30: 993-1013.
31. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008; 133: 19-25.
32. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
33. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
34. Fogarty AW, Jones S, Britton JR, et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007; 62: 515-520.
35. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-2135.
36. Rexrode KM, Pradhan A, Manson JE, et al. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003; 13: 674-682.
37. Volpato S, Pahor M, Ferrucci L, et al. Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Health, Aging, and Body Composition study. Circulation 2004; 109: 607-612.
38. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
39. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
40. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765.
41. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
42. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30: 472-478.
43. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-747.
44. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.